Literature DB >> 19617289

Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios.

Arthur R Bradwell1, Stephen J Harding, Nicolas J Fourrier, Gregg L F Wallis, Mark T Drayson, Hugh D Carr-Smith, Graham P Mead.   

Abstract

BACKGROUND: Currently, monoclonal immunoglobulins are identified and quantified from bands on electrophoretic gels. As an alternative, clonality might be determined by measuring the separate light chain types of each Ig class to allow numerical assessment of Ig'kappa/Ig'lambda ratios, analogous to free light chain kappa/lambda ratios.
METHODS: Using immunization, tolerization, and adsorption procedures, we prepared sheep antibodies against each of the 6 separate molecules, IgGkappa, IgGlambda, IgAkappa, IgAlambda, IgMkappa, and IgMlambda. Antibody targets comprised the junctional epitopes between the heavy chain and light chain domains. After purification, we assessed the antisera on a Siemens Dade-Behring BN II nephelometer for analytical quality and clinical utility.
RESULTS: High-avidity, specific antibodies allowed the production of automated nephelometric immunoassays for each Ig light chain type. Laboratory comparison with serum protein electrophoresis, using dilution experiments, showed lower analytical sensitivity for monoclonal IgG detection but similar or greater sensitivity for IgA and IgM, particularly when the monoclonal bands overlaid transferrin. Results obtained from typing of monoclonal proteins into IgG, A, or M types were comparable with results obtained by immunofixation-electrophoresis methods. Initial clinical studies, in multiple myeloma patients, indicated that Ig'kappa/Ig'lambda ratios were sometimes more sensitive than immunofixation electrophoresis, provided numerical results, and correlated with changes in disease.
CONCLUSIONS: Immunoassays for intact Ig kappa/lambda pairs are possible and should assist in the management of patients with monoclonal gammopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617289     DOI: 10.1373/clinchem.2009.123828

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  24 in total

1.  Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Beth M Faiman; Patricia Mangan; Jacy Spong; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

Review 2.  Diagnostic Advances in Multiple Myeloma.

Authors:  Kevin Barley; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

3.  Calorimetric markers for monitoring of multiple myeloma and Waldenström's macroglobulinemia patients.

Authors:  Svetla Todinova; Sashka Krumova; Avgustina Danailova; Violeta Petkova; Margarita Guenova; Georgi Mihaylov; Lidia Gartcheva; Stefka Germanova Taneva
Journal:  Eur Biophys J       Date:  2018-01-23       Impact factor: 1.733

4.  Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.

Authors:  D Zamarin; S Giralt; H Landau; N Lendvai; A Lesokhin; D Chung; G Koehne; D Chimento; S M Devlin; E Riedel; M Bhutani; D Babu; H Hassoun
Journal:  Bone Marrow Transplant       Date:  2012-08-13       Impact factor: 5.483

5.  Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Authors:  J A Katzmann; R Clark; R A Kyle; D R Larson; T M Therneau; L J Melton; J T Benson; C L Colby; A Dispenzieri; O Landgren; S Kumar; A R Bradwell; J R Cerhan; S V Rajkumar
Journal:  Leukemia       Date:  2012-07-11       Impact factor: 11.528

6.  Estimation of polyclonal IgG4 hybrids in normal human serum.

Authors:  Elizabeth Young; Emma Lock; Douglas G Ward; Alexander Cook; Stephen Harding; Gregg L F Wallis
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 7.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Authors:  A Bradwell; S Harding; N Fourrier; C Mathiot; M Attal; P Moreau; J-L Harousseau; H Avet-Loiseau
Journal:  Leukemia       Date:  2012-06-13       Impact factor: 11.528

9.  Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Authors:  Efstathios Koulieris; Panayiotis Panayiotidis; Stephen J Harding; Nikolitsa Kafasi; Dimitris Maltezas; Vassiliki Bartzis; Tatiana Tzenou; Maria Dimou; George Georgiou; Ladan Mirbahai; Arthur R Bradwell; Marie-Christine Kyrtsonis
Journal:  Exp Hematol Oncol       Date:  2012-04-23

10.  Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Authors:  H Ludwig; D Milosavljevic; N Zojer; J M Faint; A R Bradwell; W Hübl; S J Harding
Journal:  Leukemia       Date:  2012-07-17       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.